15 results
This phase I study aims to define the MTD of the combination of cisplatin/hyperthermia/lapatinib, to confirm that the 2 agents combined with hyperthermia can be administered safely, and to recommend a dose for further clinical studies.
The primary objective of this study is to compare the efficacy of eprotirome 50 microgram and eprotirome 100 micorgram versus placebo in terms of the percent change in LDL-C from baseline to Week 12 in HeFH patients with CAD, or who are at high risk…
The primary objective is to evaluate the difference in 68Ga-exendin tracer accumulation in the pancreas of patients with and without complete resolution of T2DM after RYGB by quantitative analysis of PET images.
Primary objective: To determine the efficacy of the combination of olaparib and abiraterone vs placebo and abiraterone by assessment of rPFS (Radiographic progression-free survival) in patients with mCRPC (Metastatic castration-resistant prostate…
The main objective is to examine if 68Ga-exendin tracer accumulation (i.e. beta cell mass) differs in patients with persisting HH after RYGB compared to matched patients without HH after RYGB. The secondary objectives are:- compare GLP1 and GIP…
The study will assess the safety of a sex hormone (levonorgestrel) releasing T-shaped intrauterine contraceptive system in female adolescents under 18 years of age. The incidence of adverse events over 12 month treatment period will be the main…
The main objective is to examine the change in 68Ga-exendin tracer accumulation in the pancreas (i.e. beta cell mass) after RYGB by quantitative analysis of PET images before and one year after RYGB in morbid obese patients with type 2 diabetes.
The purpose of this BIVV020 Phase 2 study is to determine the preliminary efficacy, safety, and tolerability of BIVV020 in three CIDP subpopulations including standard of care (SOC)-Treated, SOC-Refractory, and SOC-Naïve.
The purpose of this study is to evaluate the safety, pharmacokinetics, and activity of GDC-6036 combined with other anti-cancer therapies in patients with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC) that harbors a…
The purpose of this study is to determine whether 177Lu-PSMA-617, given for 6 cycles at a dose of 7.4 Gigabecquerel (GBq) (200 Millicuries (mCi)) +/- 10%, improves the radiographic progression free survival (rPFS) or death compared to a change in…
The main trial objectives are to demonstrate a non-flat dose response curve, to evaluate the size of the treatment effect (using the absolute difference in proportions of patients with histological improvement between BI 456906 and placebo at week…
Primary Objective: Phase I dose escalationThe main objective of the phase I part is to determine safety and the recommended phase II dose (RP2D) of the triple combination.Phase IIThe main objective of the phase II part is to determine efficacy of…
The purpose of this research study is to learn about the safety and effectiveness of 177Lu-PNT2002, an investigational agent being studied for patients with mCRPC who have experienced disease progression following treatment with abiraterone,…
To evaluate the Long-Term Safety and Efficacy of upadacitinib.
- To compare the effect of capivasertib + abiraterone relative to placebo + abiraterone by assessment of radiographic progression-free survival PFS) in patients with PTEN-deficient mHSPC.